Art. -Nr.: HY-12764

6-OAU

(Synonyms: GTPL5846)

6 Cited Publications

Kundenbewertung

Based on 6 publication(s) in Google Scholar

6-OAU (GTPL5846) (6-n-octylaminouracil) is an GPR84 (G protein-coupled receptor 84) agonist, with an EC₅₀ value of 105 nM. 6-OAU works as a chemoattractant to both PMNs and macrophages, and amplifies the proinflammatory cytokine IL-8, shows proinflammatory function. 6-OAU also displays anti-bacterial function.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.77%
CAS. Nr.: 83797-69-7
Formel: C₁₂H₂₁N₃O₂
Molecular Weight:239.31

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

6-OAU Chemical Structure

CAS. Nr.: 83797-69-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (6)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

ERK

Alle ERK Isoform-spezifische Produkte anzeigen :

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	0.0167 μM Compound: 3	Agonist activity at recombinant human GPR84 expressed in CHO cells co-expressing beta-galactosidase/beta-arrestin2 assessed as inhibition of forskolin-stimulated [3H]cAMP accumulation measured after 15 mins by radioactive assay Agonist activity at recombinant human GPR84 expressed in CHO cells co-expressing beta-galactosidase/beta-arrestin2 assessed as inhibition of forskolin-stimulated [3H]cAMP accumulation measured after 15 mins by radioactive assay	[PMID: 31721581]
CHO	EC₅₀	0.114 μM Compound: 3	Agonist activity at recombinant human GPR84 expressed in CHO cells assessed as beta-arrestin 2 recruitment measured after 90 mins by beta-galactosidase based PathHunter assay Agonist activity at recombinant human GPR84 expressed in CHO cells assessed as beta-arrestin 2 recruitment measured after 90 mins by beta-galactosidase based PathHunter assay	[PMID: 31721581]
HEK293	EC₅₀	0.105 μM Compound: 3	Agonist activity at recombinant human GPR84 expressed in HEK293 cells co-expressing Gqi5 assessed as increase in myo-[3H]inositol phosphate accumulation measured after 2 hrs by topcount scintillation counting method Agonist activity at recombinant human GPR84 expressed in HEK293 cells co-expressing Gqi5 assessed as increase in myo-[3H]inositol phosphate accumulation measured after 2 hrs by topcount scintillation counting method	[PMID: 31721581]
HEK293	EC₅₀	0.341 μM Compound: 3	Agonist activity at recombinant human GPR84 stably expressed in HEK293 cells co-expressing Galpha16 assessed as inhibition of forskolin-induced cAMP accumulation preincubated for 30 mins followed by forskolin addition and measured after 30 mins by HTRF as Agonist activity at recombinant human GPR84 stably expressed in HEK293 cells co-expressing Galpha16 assessed as inhibition of forskolin-induced cAMP accumulation preincubated for 30 mins followed by forskolin addition and measured after 30 mins by HTRF as	[PMID: 31721581]
HEK293	EC₅₀	0.653 μM Compound: 6-OAU	Agonist activity at GPR84 (unknown origin) expressed in HEK293 cells coexpressing Galpha16 protein by Fluo-4 AM dye based calcium mobilization assay Agonist activity at GPR84 (unknown origin) expressed in HEK293 cells coexpressing Galpha16 protein by Fluo-4 AM dye based calcium mobilization assay	[PMID: 27326330]
HEK293	EC₅₀	1.25 μM Compound: 3	Agonist activity at recombinant human GPR84 stably expressed in HEK293 cells co-expressing Galpha16 assessed as increase in intracellular calcium mobilization by Fluo-4 AM dye based fluorescence assay Agonist activity at recombinant human GPR84 stably expressed in HEK293 cells co-expressing Galpha16 assessed as increase in intracellular calcium mobilization by Fluo-4 AM dye based fluorescence assay	[PMID: 31721581]
HEK293	EC₅₀	1.75 μM Compound: 3	Agonist activity at recombinant human GPR84 expressed in HEK293 cells assessed as beta-arrestin 2 recruitment measured after 20 mins by luciferase reporter gene assay Agonist activity at recombinant human GPR84 expressed in HEK293 cells assessed as beta-arrestin 2 recruitment measured after 20 mins by luciferase reporter gene assay	[PMID: 31721581]
HEK293	EC₅₀	438 nM Compound: 6-OAU	Agonist activity at GPR84 (unknown origin) expressed in in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation preincubated for 30 mins followed by forskolin addition measured after 30 mins by HTRF assay Agonist activity at GPR84 (unknown origin) expressed in in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation preincubated for 30 mins followed by forskolin addition measured after 30 mins by HTRF assay	[PMID: 27326330]
Sf9	EC₅₀	0.512 μM Compound: 3	Agonist activity at human Gi1alpha-coupled GPR84 expressed in baculovirus infected Sf9 insect cells assessed as stimulation of [35S]GTPgammaS binding measured after 1 hr by liquid scintillation counting method Agonist activity at human Gi1alpha-coupled GPR84 expressed in baculovirus infected Sf9 insect cells assessed as stimulation of [35S]GTPgammaS binding measured after 1 hr by liquid scintillation counting method	[PMID: 31721581]
Sf9	EC₅₀	512 nM Compound: 6-OAU	Agonist activity at human GPR84 fused with bovine Galphai1 protein expressed in baculovirus infected sf9 cell membrane incubated for 1 hr by [35S]GTPgammaS binding assay Agonist activity at human GPR84 fused with bovine Galphai1 protein expressed in baculovirus infected sf9 cell membrane incubated for 1 hr by [35S]GTPgammaS binding assay	[PMID: 27326330]

In Vitro

GPR84 gene exhibits high expression in human polymorphonuclear leukocytes (PMNs) and macrophages, 6-OAU acts on proinflammatory function by activitating GPR84^[1].
6-OAU (0.01 nM-0.1 mM; 1 h) activates human GPR84 in the presence of G_qi5 chimera with an EC₅₀ value of 105 nM in HEK293 cells^[1].
6-OAU (0, 6.25, 200 μM; 30 min) stimulates [³⁵S]GTP binding, accumulates phosphoinositides, and induces GPR84-EGFP internalization in a GPR84-dependent manner^[1].
6-OAU (1 nM-1 mM; 1 h) provokes chemotaxis of PMNs in a concentration-dependent manner with an EC₅₀ value of 318 nM^[1].
6-OAU (0-10 μM; 4 h) increases the secretion of IL-8 from LPS-stimulated PMNs^[1].
6-OAU (0-0.4 μM; 16 h) also amplifies TNF-α production from U937 macrophages^[1].
6-OAU (2 μM; 4 h) decreases ERK phosphorylation and MCP-1 protein expression, (2 μM; 48 h) decreases MCP-1 secretion in macrophages ^[2].
6-OAU (2 μM; 24 h) reduces ROS production during B. abortus infection in RAW264.7 cells^[2].
6-OAU (2 μM; 0, 30, and 60 min) inhibits adhesion and Brucella uptake in RAW264.7 cells and (2 μM; 30 min) shows anti-infection against Brucella and Salmonella infection^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

B. abortus
Concentration:

0, 0.02, 0.2, 2 μM
Incubation Time:

0, 2, 24, 48, 72 hours
Result:

Decreased B. abortus survivability begin at 48 h with a dose of 2 μM.

Western Blot Analysis^[2]

Cell Line:

RAW264.7 cells infected with B. abortus
Concentration:

2 μM
Incubation Time:

4 hours
Result:

Reduced ERK phosphorylation and MALT1 expression in RAW264.7 macrophages.

In Vivo

6-OAU activates GPR84 and results in making an inflammatory condition through chemokine production and chemotaxis in vivo^[1].
6-OAU (10 mg/kg; i.v.) raises the blood CXCL1 level in rats^[1].
6-OAU (1 mg/mL; s.c.) attracts both PMNs and macrophages into the air pouch^[1].
6-OAU (2 μM, 100 mL/mouse; s.c.) augments resistance to Brucella infection, and reduces bacterial proliferation in spleens and livers^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female Lewis rats(4-week-old)^[1]
Dosage:

10 mg/kg
Administration:

Intravenous injection; collecting blood 3 h after injection
Result:

Increased the elevation of a chemokine, CXCL1 concentration in the serum peaking at 3 h after the injection.

Animal Model:

Rat air pouch model (4-week-old female rats)^[1]
Dosage:

1 mg/mL (PBS)
Administration:

Subcutaneous injection; washing the cavity 4 h after injection
Result:

Attracted both PMNs and macrophages into the air pouch, peaking at 4 h after the injection.

Animal Model:

ICR female mice (7-week-old)^[2]
Dosage:

2 μM (100 μL/mouse)
Administration:

Oral average; 7 days and another 14 days after treated mouse with B. abortus (2 × 105 CFU /100 μL; i.p.)
Result:

Reduced bacterial proliferation in the liver and spleen, and decreased IFN-γ but augmented IL-6 serum level.
Lowed splenic weight of mice and splenic proliferation.

Chemical Information

CAS. Nr. 83797-69-7
Appearance Solid
Molecular Weight 239.31
Formel C₁₂H₂₁N₃O₂
Color Light yellow to yellow
SMILES

O=C1NC(C=C(NCCCCCCCC)N1)=O
Synonyms

GTPL5846
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (6)

All

Sort by:

Journal Impact Factor

J Clin Invest

GPR84-mediated signal transduction effects metabolic function by promoting brown adipocyte activity. [Abstract]

2023 Dec 15;133(24):e168992. PMID: 37856216
Cancer Immunol Res

Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T cells Antitumor Immunity Through Metabolic Reprogramming. [Abstract]

2026 Jan 20. PMID: 41557755
J Ethnopharmacol

Isobavachalcone ameliorates TNBS-induced Crohn's disease-like colitis via GPR84-PI3K-AKT axis. [Abstract]

2025 Sep 8;355(Pt A):120575. PMID: 40930295
Int Immunopharmacol

A novel GPR84 antagonist attenuates diabetic lung injury by inhibiting pyroptosis via the cGAS-STING pathway in pulmonary vascular endothelial cells. [Abstract]

2025 Jul 21:163:115190. PMID: 40695150
Naunyn Schmiedebergs Arch Pharmacol

Label-free cell phenotypic profiling of sphingosine-1-phosphate receptor 1 and discovery of its agonist from natural products. [Abstract]

2026 May 29. PMID: 42209736
J Radiat Res Appl Sci

2026 Apr 5;19(2):102360.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 25 mg/mL (104.47 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.1787 mL

20.8934 mL

41.7868 mL

5 mM

0.8357 mL

4.1787 mL

8.3574 mL

10 mM

0.4179 mL

2.0893 mL

4.1787 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 5% DMSO 95% Corn Oil

Solubility: ≥ 1.25 mg/mL (5.22 mM); Clear solution

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Suzuki M, et al. Medium-chain fatty acid-sensing receptor, GPR84, is a proinflammatory receptor. J Biol Chem. 2013 Apr 12;288(15):10684-91. [Content Brief]

[2]. Reyes AWB, et al. Immune-metabolic receptor GPR84 surrogate and endogenous agonists, 6-OAU and lauric acid, alter Brucella abortus 544 infection in both in vitro and in vivo systems. Microb Pathog. 2021 Sep. 158:105079. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.1787 mL	20.8934 mL	41.7868 mL	104.4670 mL
	5 mM	0.8357 mL	4.1787 mL	8.3574 mL	20.8934 mL
	10 mM	0.4179 mL	2.0893 mL	4.1787 mL	10.4467 mL
	15 mM	0.2786 mL	1.3929 mL	2.7858 mL	6.9645 mL
	20 mM	0.2089 mL	1.0447 mL	2.0893 mL	5.2234 mL
	25 mM	0.1671 mL	0.8357 mL	1.6715 mL	4.1787 mL
	30 mM	0.1393 mL	0.6964 mL	1.3929 mL	3.4822 mL
	40 mM	0.1045 mL	0.5223 mL	1.0447 mL	2.6117 mL
	50 mM	0.0836 mL	0.4179 mL	0.8357 mL	2.0893 mL
	60 mM	0.0696 mL	0.3482 mL	0.6964 mL	1.7411 mL
	80 mM	0.0522 mL	0.2612 mL	0.5223 mL	1.3058 mL
	100 mM	0.0418 mL	0.2089 mL	0.4179 mL	1.0447 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

6-OAU

Anti-Infection Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Stem Cell Signaling Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Antibacterial Compound Library

Glutamine Metabolism Compound Library

Antibiotics Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Chemokine Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Serine/Threonine Kinase Inhibitor Library

Macrophage Related Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) 6-OAU

Alle ERK Isoform-spezifische Produkte anzeigen

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (6)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

6-OAU Related Classifications

HY-12764 Related Classifications